Martin Becker

Former President & Chief Executive Officer at XTL Biopharmaceuticals Ltd.

Martin Becker

Martin Becker

Former President & Chief Executive Officer at XTL Biopharmaceuticals Ltd.

Overview
Career Highlights

Resolvyx Pharmaceuticals, Inc.
XTL Biopharmaceuticals Ltd.
CaloSyn Pharma, Inc.

RelSci Relationships

223

Number of Boards

1

Relationships
RelSci Relationships are individuals Martin Becker likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Profusa, Inc.

Relationship likelihood: Average

Co-Founder, Chief Executive Officer at Truffle Capital

Relationship likelihood: Average

Associate Professor at Karolinska Institutet

Relationship likelihood: Average

Former President & Chief Executive Officer at ImaginAb, Inc.

Relationship likelihood: Average

Founder at Arrow Therapeutics Ltd.

Relationship likelihood: Average

Executive Chairman at Calchan Ltd.

Relationship likelihood: Average

Managing Director at Novartis Venture Fund

Relationship likelihood: Average

Former Non-Executive Director at Altimmune UK Ltd.

Relationship likelihood: Average

Partner at Healthcap Advisor AB

Relationship likelihood: Average

Head of Business Development at Protein Sciences Corporation

Relationship likelihood: Average

Paths to Martin Becker
Potential Connections via
Relationship Science
You
Martin Becker
Former President & Chief Executive Officer at XTL Biopharmaceuticals Ltd.
Education
Doctorate Degree

The Weizmann Institute of Science is one of the world’s leading multidisciplinary research institutions. Hundreds of scientists, laboratory technicians and research students working on its lushly landscaped campus embark daily on fascinating journeys into the unknown, seeking to improve our understanding of nature and our place within it. Lettuce fieldGuiding these scientists is the spirit of inquiry so characteristic of the human race. It is this spirit that propelled humans upward along the evolutionary ladder, helping them reach their utmost heights. It prompted humankind to pursue agriculture, learn to build lodgings, invent writing, harness electricity to power emerging technologies, observe distant galaxies, design drugs to combat various diseases, develop new materials and decipher the genetic code embedded in all the plants and animals on Earth. The quest to maintain this increasing momentum compels Weizmann Institute scientists to seek out places that have not yet been reached by the human mind. What awaits us in these places? No one has the answer to this question. But one thing is certain – the journey fired by curiosity will lead onward to a better future. Groundbreaking medical and technological applications that have emerged from basic research conducted by Weizmann Institute scientists include: Amniocentesis, a prenatal diagnostic test for the fetus neonatal Sophisticated laser systems for high-precision diamond cutting A method for growing hybrid seeds that prevents the transmission of disease from one generation to the next and helps protect edible plants from pests Affinity chromatography, a key tool for purifying biological materials in the biotechnology industry Living polymerization, one of the most fundamental techniques of the modern polymer industry For solving the structure of the ribosome, the cell’s protein factory, and revealing its means of action, the Institute’s Prof. Ada Yonath was awarded a Nobel Prize in Chemistry. Her research should speed the development of antibiotic drugs that are more efficient, especially against antibiotic-resistant strains

Undergraduate Degree

The University of Wisconsin–Madison has long been recognized as one of America's great universities. A public, land-grant institution, UW–Madison offers a complete spectrum of liberal arts studies, professional programs and student activities. Spanning 936 acres along the southern shore of Lake Mendota, the campus is located in the city of Madison.

Career History
Chief Executive Officer
Prior

Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in June 20, 2001 and is headquartered in Cambridge, MA.

President & Chief Executive Officer
Prior

XTL Biopharmaceuticals Ltd. focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.

President & Chief Executive Officer
Prior

Calosyn Pharma, Inc. develops intra-articular therapeutics for osteoarthritis. Its product is based on a class of drugs known as calcium channel blockers. The firm's drugs is used in humans for the treatment of heart and vascular diseases. The company was founded by David D. Waddell and is headquartered in Atlanta, GA.

Boards & Committees
Director
Prior

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Martin Becker. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Martin Becker's profile does not indicate a business or promotional relationship of any kind between RelSci and Martin Becker.